Member Info for draft

Im still in - im looking for a big contract announcement supporting Ramky in Oman or UAE hopefully

like they dont realy care about the Italian stuff and the website doesnt really go into any details on it Just looks like all Indonesia focused. Theres a chance they could do a coup and get a big asset

same here i bought right at the top.

not out of the question . stronger business, burton, strong macro environment, big sticky holders holding the base together, etc etc you know the score.... i see no reason why this cant get to 20p plus. timescale unknown of course.

must know something ,

Looks like a Thai massage parlour

hopefully get back to 8p over time

Braveheart Investment Group plc is a private equity and venture capital firm specializing in start-up, early stage, expansion stage, turnaround, restructuring, management buy-out, management buy-in, loan and mezzanine funding, and follow-on and secondary purchase stage investments in unquoted emerging companies. Braveheart Investment Group was founded in 1997 and with the company�s market capitalisation at GBP �4.54M, we can put it in the small-cap category. BRH�s stock is currently hovering at around -29% lower than its intrinsic value of �0.24, at a price tag of �0.17, based on its expected future cash flows. This mismatch signals an opportunity to buy BRH shares at a discount.

Basel, Switzerland, 12 February 2018 � Today Lonza announced the latest addition to its cell-culture product portfolio � the Quasi Vivo System. The Quasi Vivo Device consists of an advanced, interconnected fluidics system to create more physiologically relevant cell-culture conditions, helping researchers improve the predictive value of their studies. This new product offering from Lonza is a result of a worldwide marketing and distribution agreement with Kirkstall � a biotechnology company based in Rotherham (UK).

Poster Presentation: A Novel In Vitro Liver Cell Culture Flow System Allowing Long-term Metabolism and Hepatotoxicity Studies On Monday, 12 March, from 10:45 am�12:15 pm in the Exhibit Hall, Magdalene Stosik, Senior Scientist RND-Cell Biology at Lonza, will describe how the Quasi Vivo� Culture System can improve metabolism and hepatotoxicity studies. While animal models are useful for detecting hepatotoxicity, they are often unable to accurately predict toxicity in humans due to species differences. However, by culturing primary human hepatocytes in an advanced, interconnected fluidics system, the stability of drug metabolism enzymes can be improved, offering a more representative in vitro model for the repeated dosing of hepatotoxicants.

https://d1ssu070pg2v9i.cloudfront.net/pex/rockroseenergy/2018/02/14142233/Rockrose-Prospectus-12-02-18.pdf

bothered to call the board?

yes KIN will rocket on a deal. that's why i hold. lol you knocking his army experience. he will be well connected and know senior leadership.

i still think this can do well from here as the trevor fiasco would have caused some panic selling and the price didnt drop much.

of course the sellers still about ppl loaded up at 5p the clever investors did anyway. at one point i had these at 3.75

i haven't sold - i m a sucker for punishment .

think this has serious legs with solid state in the news right now

nice and easy - gentle throttle

prefer gentle climb

i have No intention of selling so dont really care when they come back. Just enjoy this party!